Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**DAB486-G-CSF** is an experimental recombinant fusion toxin comprising a 486-amino-acid diphtheria toxin-derived cytotoxic domain genetically linked to human granulocyte colony-stimulating factor. The G-CSF domain targets cells expressing the granulocyte colony-stimulating factor receptor, including G-CSF-responsive acute myeloid leukemia cells, enabling uptake of the toxin moiety. Intracellular diphtheria-toxin enzymatic activity ADP-ribosylates elongation factor 2, thereby inhibiting protein synthesis and causing cell death. In preclinical studies, the construct was cytotoxic to G-CSF-dependent OCI/AML1 cells and inhibited colony formation by G-CSF-responsive leukemic blasts from a patient with acute myeloid leukemia, while sparing factor-independent OCI/AML3 cells. ([europepmc.org](https://europepmc.org/article/MED/7505148))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DAB486-G-CSF.